In the past 20 years, the availability of tumor necrosis factor inhibitors (TNFis) and other biologic disease-modifying antirheumatic drugs (bDMARDs) has transformed treatment for patients with rheumatoid arthritis (RA). This evidence concerns the gene TNF and rheumatoid arthritis.